Literature DB >> 18626134

Effects of vestibular training on motion sickness, nystagmus, and subjective vertical.

Gilles Clément1, Olivier Deguine, Mathieu Bourg, Anne Pavy-LeTraon.   

Abstract

Pitch head-and-trunk movements during constant velocity rotation are a provocative vestibular stimulus that produces vertigo and nausea. When exposed to this stimulus repeatedly, motion sickness symptoms diminish as the subjects habituate. Acetylleucine is a drug that is used to treat acute vestibular vertigo. In this study, we wanted to ascertain whether this drug (a) lessened motion sickness or delayed habituation; (b) accelerated the recovery following habituation; and (c) whether changes in the subjective vertical accompanied habituation. Twenty subjects were administered acetylleucine or placebo in a double-blind study during a five-day vestibular training. Horizontal vestibulo-ocular reflex, optokinetic nystagmus, smooth pursuit, and subjective visual vertical were evaluated before, during, and up to two months after the vestibular training. Based on Graybiel's diagnostic criteria, motion sickness decreased steadily in each vestibular training session, and there was no difference between the scores in the acetylleucine and placebo groups. Post-rotatory nystagmus peak velocity and time constant also declined in both groups at the same rate. Thus, acetylleucine neither reduced the nausea associated with this provocative stimulus, nor hastened the acquisition or retention of vestibular habituation of motion sickness and nystagmus. There was no difference in optokinetic nystagmus and smooth pursuit between the acetylleucine and placebo groups. However, subjects showed larger error in the subjective visual vertical after habituation, which indicates that spatial orientation is also affected by vestibular training.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18626134

Source DB:  PubMed          Journal:  J Vestib Res        ISSN: 0957-4271            Impact factor:   2.435


  8 in total

1.  Vestibular functions in motion sickness susceptible individuals.

Authors:  Fuat Buyuklu; Erkan Tarhan; Levent Ozluoglu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-02-26       Impact factor: 2.503

2.  Motion sickness and sense of presence in a virtual reality environment developed for manual wheelchair users, with three different approaches.

Authors:  Zohreh Salimi; Martin William Ferguson-Pell
Journal:  PLoS One       Date:  2021-08-19       Impact factor: 3.240

3.  Retention of habituation of vestibulo-ocular reflex and sensation of rotation in humans.

Authors:  Gilles Clément; Caroline Tilikete; Jean-Hubert Courjon
Journal:  Exp Brain Res       Date:  2008-07-01       Impact factor: 1.972

Review 4.  Interventions for eye movement disorders due to acquired brain injury.

Authors:  Fiona J Rowe; Kerry Hanna; Jennifer R Evans; Carmel P Noonan; Marta Garcia-Finana; Caroline S Dodridge; Claire Howard; Kathryn A Jarvis; Sonia L MacDiarmid; Tallat Maan; Lorraine North; Helen Rodgers
Journal:  Cochrane Database Syst Rev       Date:  2018-03-05

Review 5.  Moving in a Moving World: A Review on Vestibular Motion Sickness.

Authors:  Giovanni Bertolini; Dominik Straumann
Journal:  Front Neurol       Date:  2016-02-15       Impact factor: 4.003

6.  Individual motion perception parameters and motion sickness frequency sensitivity in fore-aft motion.

Authors:  Tugrul Irmak; Ksander N de Winkel; Daan M Pool; Heinrich H Bülthoff; Riender Happee
Journal:  Exp Brain Res       Date:  2021-03-29       Impact factor: 1.972

7.  Postural Effects of Vestibular Manipulation Depend on the Physical Activity Status.

Authors:  Julien Maitre; Thierry Paillard
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

8.  Floccular fossa size is not a reliable proxy of ecology and behaviour in vertebrates.

Authors:  S Ferreira-Cardoso; R Araújo; N E Martins; G G Martins; S Walsh; R M S Martins; N Kardjilov; I Manke; A Hilger; R Castanhinha
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.